- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02706223
Testing and Treating Hepatitis C in Community Pharmacies (SuperDOT-C)
A Cluster Randomised Trial of Pharmacy Led HCV Therapy Versus Conventional Treatment Pathways for HCV Positive Patients Receiving Daily OST in Pharmacies in Health Boards Within NHS Scotland
Hepatitis C Virus, (HCV), infection is a major health concern in the UK with up to 0.7% of the population infected. At best, 25% of those infected will clear the infection spontaneously, though for those who develop a chronic infection, they may go onto to develop liver cirrhosis or liver cancers.
The standard of care within the NHS is that patients with a history of intravenous drug use or those currently on methadone are at high risk of having HCV infection and should be offered HCV testing. Once diagnosed they can be referred to nurse led treatment pathways. Less than 10% of the methadone users are even tested for HCV and of them fewer than 20% go onto treatment regimens that successfully clear the infection despite regular interactions with heath care staff.
Pharmacists who have daily interactions with patients receiving methadone are ideally placed to deliver anti HCV therapy as they have daily contact with this client group and are well placed to advise on the drug therapy.
The SuperDOT C study will examine the impact of pharmacy led Directly Observed Therapy (DOT) for HCV treatment in patients attending Community Pharmacies in participating Health Boards within NHS Scotland. The impact of this approach will be compared with those referred to standard care pathways on how well participants clear their HCV infection.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Aberdeen, Royaume-Uni, AB25 2ZN
- NHS Grampian
-
Dundee, Royaume-Uni, DD1 9SY
- NHS Tayside
-
Glasgow, Royaume-Uni, G$ 0SF
- NHS Greater Glasgow and Clyde
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- HCV PCR positive,
- Stable OST dose for greater than 12 weeks prior to study enrolment
Exclusion Criteria:
- Evidence of current or previous decompensated liver disease,
- Currently receiving HCV eradication treatment
- HIV infection,
- HBsAg positive with detectable HBV DNA,
- Pregnancy
- Cirrhosis or high fibrosis score
- Genotype deemed unsuitable for treatment with available study drugs
- Unable or unwilling to provide informed consent
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Recherche sur les services de santé
- Répartition: Randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Pharmacist Led
This arm involved subjects following pathway of care and treatment delivery delivered by community pharmacists
|
Trial of administering established, licensed treatments by a novel pathway, ie Community Pharmacists, which is hypothesized to improve treatment and retention in treatment of difficult to engage subjects
|
Expérimental: Nurse Led
This arm involved subjects following the conventional pathway of care and treatment delivery delivered by specialist secondary care nurses
|
Trial of administering established, licensed treatments by the conventional clinical care pathway, ie Specialist nurses
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Rate of Sustained Viral Response at 12 weeks, (SVR12), in pharmacy pathway compared with that of the current treatment pathway 12 weeks after completion of HCV therapy
Délai: 12 week SVR, (12 weeks post completion of HCV treatment)
|
Blood test result; PCR - based measurement of levels of hepatitis C virus.
|
12 week SVR, (12 weeks post completion of HCV treatment)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Cost effectiveness of the pharmacist pathway as compared with the conventional care pathway
Délai: Span of study ie 24 months
|
Health economics analysis
|
Span of study ie 24 months
|
To determine whether the Pharmacist-led pathway compared with the Conventional Pathway leads to more people on OST being tested and initiating treatment
Délai: Span of study ie 24 months
|
Comparison of rate of HCV testing rates in pharmacist pathway compared with current pathway
|
Span of study ie 24 months
|
To explore whether adherence and persistence to HCV therapy in the pharmacy setting is at least similar to that in the Conventional pathway
Délai: Span of study ie 24 months
|
Comparison of compliance rates of antiviral medications between pharmacist and conventional pathway.
|
Span of study ie 24 months
|
To compare the acceptability of the Pharmacist-led pathway versus the conventional treatment pathway for OST clients
Délai: Span of study ie 24 months
|
Compare the acceptability of the pharmacist pathway as compare to conventional pathway of care
|
Span of study ie 24 months
|
To measure re-infection rate at 1 year after end of treatment in patients with SVR
Délai: Span of study ie 24 months
|
Comparison of the rate of reinfections with HCV between pharmacist and conventional pathways
|
Span of study ie 24 months
|
To compare the number of patients who drop out of the study between the two pathways
Délai: Span of study ie 24 months
|
Comparison of subject drop out rates between pharmacist and conventional pathways
|
Span of study ie 24 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: John F Dillon, MD, University of Dundee
Publications et liens utiles
Publications générales
- Radley A, de Bruin M, Inglis SK, Donnan PT, Hapca A, Barclay ST, Fraser A, Dillon JF. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial. Lancet Gastroenterol Hepatol. 2020 Sep;5(9):809-818. doi: 10.1016/S2468-1253(20)30120-5. Epub 2020 Jun 8.
- Hickman M, Dillon JF, Elliott L, De Angelis D, Vickerman P, Foster G, Donnan P, Eriksen A, Flowers P, Goldberg D, Hollingworth W, Ijaz S, Liddell D, Mandal S, Martin N, Beer LJZ, Drysdale K, Fraser H, Glass R, Graham L, Gunson RN, Hamilton E, Harris H, Harris M, Harris R, Heinsbroek E, Hope V, Horwood J, Inglis SK, Innes H, Lane A, Meadows J, McAuley A, Metcalfe C, Migchelsen S, Murray A, Myring G, Palmateer NE, Presanis A, Radley A, Ramsay M, Samartsidis P, Simmons R, Sinka K, Vojt G, Ward Z, Whiteley D, Yeung A, Hutchinson SJ. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol). BMJ Open. 2019 Sep 24;9(9):e029538. doi: 10.1136/bmjopen-2019-029538.
- Radley A, de Bruin M, Inglis SK, Donnan PT, Dillon JF. Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial. BMJ Open. 2018 Dec 14;8(12):e021443. doi: 10.1136/bmjopen-2017-021443.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2014GA07
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Pharmacist Led
-
University of Nove de JulhoInconnueTrouble temporo-mandibulaireBrésil
-
New York Institute of TechnologyRecrutementDouleur chronique | Syndrome d'Ehlers-DanlosÉtats-Unis
-
University of BergenGlamoxComplétéDormir | Privation de sommeil | Troubles du sommeil liés au travail postéNorvège
-
University of Nove de JulhoInconnue
-
Erebouni Medical CenterRecrutementHyperbilirubinémie néonatale | Jaunisse néonataleArménie
-
Kaohsiung Medical UniversityComplétéTroubles du sommeil | Démence | Déficience cognitive légère | PhotothérapieTaïwan
-
Illumacell Inc.Kerber Applied Research; Alberta Health Services - Lower Limb Wound ClinicComplétéUlcère du pied diabétiqueCanada
-
VA Office of Research and DevelopmentComplétéManifestations neurocomportementales | Troubles de la mémoire | Maladie des vétérans de la guerre du GolfeÉtats-Unis
-
Academic Centre for Dentistry in AmsterdamPas encore de recrutementMyélome multiple
-
Centro de Atenção ao Assoalho PélvicoRecrutement